Business Description
Actavia Life Sciences Inc
NAICS : 325412
SIC : 2834
ISIN : US7538881068
Description
Actavia Life Sciences Inc is a clinical-stage biotechnology company focused on targeted drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Its primary indication is Acute Myeloid Leukemia (AML), which may be fatal within weeks to months, has about a 5-year survival rate of only about 25% and very poor prospects for the long-term survival of patients.
Financial Strength
| Name | Current | Vs Industry | Vs History |
|---|
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
6-1 Month Momentum % | -87.5 | |||||
12-1 Month Momentum % | -87.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History |
|---|
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Value Rank
| Name | Current | Vs Industry | Vs History |
|---|
GF Valueâ„¢
Actavia Life Sciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Actavia Life Sciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| 3.25:1 Stock Split | 2016-09-20 | 0.46 (+0.00%) |
Show
Entries
Guru Commentaries on OTCPK:RASP
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Actavia Life Sciences Inc
No articles.